Form 4: Castle Biosciences CEO Sells Shares Under 10b5-1 Plan

Castle Biosciences' President and CEO, Derek J. Maetzold, sold 9,373 shares of common stock in early November 2025, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• Derek J. Maetzold, President and Chief Executive Officer, and a Director of Castle Biosciences Inc. (CSTL), reported sales of common stock.
• A total of 9,373 shares were sold across three transactions on November 4 and November 5, 2025.
• The sales were executed under a Rule 10b5-1 plan adopted by Mr. Maetzold on May 8, 2025.
• On November 4, 2025, 6,458 shares were sold at a weighted-average price of $30.413 per share.
• Also on November 4, 2025, an additional 237 shares were sold at a weighted-average price of $31.117 per share.
• On November 5, 2025, 2,678 shares were sold at a weighted-average price of $31.851 per share.
• Following these transactions, Mr. Maetzold directly beneficially owns 53,615 shares of common stock.
• Indirect beneficial ownership includes shares held by various trusts, totaling 261,372 shares, bringing total beneficial ownership to 314,987 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the sales represent a reduction in direct insider ownership, the fact that they were conducted under a pre-arranged 10b5-1 plan mitigates the immediate negative implications, suggesting a planned diversification rather than a reaction to adverse company news.

Negatives

• The President and CEO reduced his direct beneficial ownership in the company by selling 9,373 shares.
• While pre-planned, insider selling can sometimes be perceived by the market as a lack of confidence, even if for personal diversification.

Risks

• The sale of shares by a key executive, even under a 10b5-1 plan, could be misinterpreted by investors as a negative signal regarding the company's future prospects, potentially leading to downward pressure on the stock price.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Shares are indirectly held by various trusts, including The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trusts (FBO Emily Carol Kirk, Hannah Elizabeth Maetzold, John Derek Maetzold, Peter Douglas Maetzold), and DJM Grantor Retained Annuity Trusts (No. 5, No. 6, No. 7). These trusts involve the reporting person, his spouse, and children as trustees or beneficiaries.

Stakeholder Impact

• Shareholders may view the executive's sale of shares, even if pre-planned, with caution, potentially influencing investor sentiment and short-term stock price movements.
• The transactions do not directly impact employees, customers, suppliers, or creditors, as they relate to personal stock holdings of an executive.

Key Dates

Recommendation

The insider sales by the CEO, while significant in volume, were conducted under a pre-arranged Rule 10b5-1 plan. This suggests a planned diversification or liquidity event rather than a reaction to new, negative company-specific information. Therefore, while not a positive signal, it does not necessarily warrant a 'sell' recommendation. Investors should 'hold' and monitor future company performance and other market indicators, as this transaction alone does not fundamentally alter the investment thesis for Castle Biosciences.

Keywords

Castle Biosciences, CSTL, Derek J. Maetzold, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Executive Compensation, Beneficial Ownership